In this context, we have recently demonstrated that HTLA-230, a MYCN-amplified human NB cell line chronically treated with the clinically-used drug etoposide10, developed etoposide-resistance and also acquired a multi-drug resistance (MDR) phenotype, thus becoming able to efficiently repair DNA damage and evade apoptosis11. Here, MYCN is linked to neuroblastoma.